Jump to content
Powered by

Pharmaceutics

The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg

  • Press release - 21/04/2021

    Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.

  • Press release - 13/04/2021

    Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

  • Press release - 30/03/2021

    CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on mRNA and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization specializing in the development and production of Advanced Therapy Medicinal Products and mammalian cell line-expressed bio-therapeutics, announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.

  • Press release - 24/03/2021

    Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

  • Press release - 24/03/2021

    Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

  • Microfluidics in medical technology - 24/03/2021

    Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.

  • Press release - 23/03/2021

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.

  • Press release - 04/03/2021

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway.

  • Press release - 24/02/2021

    Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes.

  • Article - 14/01/2021

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

  • Digitalisation in Medicine - 08/12/2020

    Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/pharma